Milestone Pharmaceuticals Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Milestone Pharmaceuticals Inc. (MIST) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $0.00.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-03-31 was $0.00.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $1.55M.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $0.00.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $1.55M.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $1.00M, a 80.00% decline from fiscal 2022.
- Milestone Pharmaceuticals Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $5.00M, a 66.67% decline from fiscal 2021.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $1.55M derived: sum of 3 quarters · filed 2026-08-12 | $1.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $1.55M derived: sum of 2 quarters · filed 2026-05-13 | $1.55M derived: sum of 3 quarters · filed 2026-05-13 | $1.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.55M derived: sum of 2 quarters · filed 2026-03-20 | $1.55M derived: sum of 3 quarters · filed 2026-08-12 | $1.55M 10-K · filed 2026-03-20 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $0.00 derived: sum of 2 quarters · filed 2026-03-20 | $0.00 derived: sum of 3 quarters · filed 2026-03-20 | $0.00 10-K · filed 2026-03-20 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $0.00 derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | $0.00 derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $1.00M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $1.00M 10-Q · filed 2024-11-12 | $4.50M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $1.00M 10-Q · filed 2024-08-08 | $4.50M derived: sum of 3 quarters · filed 2024-08-08 | $6.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-13 | $4.50M derived: sum of 2 quarters · filed 2024-05-13 | $6.00M derived: sum of 3 quarters · filed 2024-05-13 | $6.00M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.00M derived: sum of 2 quarters · filed 2024-03-21 | $5.00M derived: sum of 3 quarters · filed 2024-03-21 | $5.00M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-13 | $1.50M derived: sum of 2 quarters · filed 2023-11-13 | $1.50M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $15.00M derived: sum of 3 quarters · filed 2023-03-29 | $15.00M 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $15.00M derived: sum of 2 quarters · filed 2022-11-10 | $15.00M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $15.00M 10-Q · filed 2022-08-10 | $15.00M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |